Clinical Research Directory

Inclusion Criteria: * ASA score less then 3, Signed inform consent, Absence of preoperative drugs administration that affects patient's perception of pain, No active infection process, BMI index \>18,5 kg\\m2 and \< 35 kg/m2, CABG, Age 18-75 years Exclusion Criteria (the presence of at least one is sufficient): * Failure to meet the inclusion criteria. * High severity according to ASA (class IV or higher), which is associated with a high probability of prolonged mechanical ventilation, hemodynamic instability, and inability to use drugs affecting cardiac output and/or total peripheral vascular resistance. * Contraindications to the use of tafalgin and/or morphine in accordance with the approved Summary of Product Characteristics (hypersensitivity to tafalgin, morphine, other opioids, or any excipients). * Pregnancy or lactation. * Acute or prolonged chronic intoxication with drugs or substances depressing the central nervous system (alcohol, barbiturates, opioid drugs, benzodiazepines). * Use of monoamine oxidase inhibitors (MAOIs) or less than 14 days since their discontinuation. * Liver cirrhosis, Child-Pugh class C. * Acute renal failure requiring renal replacement therapy. * Unresected malignant neoplasm. * Mesenteric thrombosis or another severe abdominal pain syndrome of unclear etiology at the time of inclusion. * Simultaneous participation in another clinical study. * Marked CNS depression due to any cause, except for acute poisoning. * COPD stage III and/or bronchial asthma in the exacerbation phase. * Any clinically significant condition, disease, or circumstance in the medical history that, in the opinion of the investigator, precludes participation in the study. * Psychiatric, physical, or other conditions preventing adequate assessment of the patient's behavior or proper compliance with the study protocol. * Postoperative hemodynamic instability requiring high-dose inotropic and/or vasopressor support (epinephrine \> 0.1 μg/kg/min, dopamine \> 10 μg/kg/min, norepinephrine \> 0.2 μg/kg/min) and/or mechanical circulatory support. * Refusal to participate in the study.